Rigel Pharmaceuticals (RIGL) Return on Equity (2011 - 2026)

Rigel Pharmaceuticals has reported Return on Equity for 16 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 2.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (down 2.0% YoY), and the FY2025 full-year result was 0.02%, up 3.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, down from 0.01% in the prior quarter.
• The five-year high for Return on Equity was 0.07% in Q3 2022, with the low at 0.54% in Q2 2022.
• Average Return on Equity over 5 years is 0.02%, with a median of 0.01% recorded in 2026.
• Year-over-year, Return on Equity sank 54 bps in 2022 and soared 56 bps in 2023.
• Tracing RIGL's Return on Equity over 5 years: stood at 0.04% in 2022, then slumped by 76 bps to 0.01% in 2023, then plunged by 471 bps to 0.03% in 2024, then surged by 147 bps to 0.01% in 2025, then slumped by 36 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.

Peer Comparison